Xu H, Kaye JA, Saltus CW, Crawford J, Gasa E, Goodnough LT. Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents. Expert Rev Hematol. 2014 Oct;7(5):617-33. doi: 10.1586/17474086.2014.943730
Garcia-Albeniz X, Martinez-Fernandez A, Gascon P. Combining targeted therapies. Target Oncol. 2007 Oct;2(4):241-52. doi: 10.1007/s11523-007-0062-5
Rodríguez S, Gaunt TR, O'Dell SD, Chen XH, Gu D, Hawe E, Miller GJ, Humphries SE, Day IN. Haplotypic analyses of the IGF2-INS-TH gene cluster in relation to cardiovascular risk traits. Hum Mol Genet. 2004 Apr;13(7):715-25.
Williams LK, Pladevall-Vila M, Fendrick AM, Lafata JE, McMahon LF. Differences in the reporting of care-related patient injuries to existing reporting systems. Jt Comm J Qual Patient Saf. 2003 Sep;29(9):460-7.
Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, Pennacchio LA, Humphries SE. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet. 2002;11(24):3039-46.